Drug Overview
Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; Otsuka/Lundbeck), displaying partial agonism of dopamine receptors in the central nervous system.
In November 2011, Otsuka announced that it had signed a long-term agreement with Lundbeck for the development and commercialization of central nervous system products in both companies’ pipelines. Rexulti was one of Otsuka’s key assets in the deal. In return for $200m upfront, with a potential final deal value of $1.8bn, Lundbeck gained co-development and co-promotion rights to Rexulti and a depot formulation of Abilify. Lundbeck also offered Otsuka the same rights for up to three of its compounds after Phase IIb clinical trials.
Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; Otsuka/Lundbeck), displaying partial agonism of dopamine receptors in the central nervous system.
In November 2011, Otsuka announced that it had signed a long-term agreement with Lundbeck for the development and commercialization of central nervous system products in both companies’ pipelines. Rexulti was one of Otsuka’s key assets in the deal. In return for $200m upfront, with a potential final deal value of $1.8bn, Lundbeck gained co-development and co-promotion rights to Rexulti and a depot formulation of Abilify. Lundbeck also offered Otsuka the same rights for up to three of its compounds after Phase IIb clinical trials.
Table of Contents
OVERVIEW- Drug Overview
- Product Profiles
- Rexulti: Depression
- Rexulti: Bipolar disorder
- Rexulti: Schizophrenia
LIST OF FIGURES
Figure 1: The author's drug assessment summary of Rexulti for depression
Figure 2: The author's drug assessment summary of Rexulti for depression
Figure 3: Rexulti sales for depression across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Rexulti for bipolar disorder – SWOT analysis
Figure 5: Rexulti for schizophrenia – SWOT analysis
Figure 6: The author's drug assessment summary of Rexulti for schizophrenia
Figure 7: The author's drug assessment summary of Rexulti for schizophrenia
Figure 8: Rexulti sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
Table 1: Rexulti drug profile
Table 2: Approval history of Rexulti for depression in the US
Table 3: Late-phase trials of Rexulti for depression
Table 4: Rexulti ongoing Phase III trials in depression
Table 5: Rexulti for depression – SWOT analysis
Table 6: Rexulti drug profile
Table 7: Rexulti Phase III trials in bipolar mania
Table 8: Rexulti Phase IV trial in bipolar depression
Table 9: Rexulti drug profile
Table 10: Rexulti pivotal trial data in schizophrenia
Table 11: Rexulti sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
